España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Mydecine Innovations Gr
MYCOF
OTCPK
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$0.006900
0.0016
31.18%
At close: -
Get Report
Comment
Mydecine Innovations Gr (MYCOF) Forecast
News
Earnings
Mydecine Innovations Gr (MYCOF) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Mydecine Innovations Gr (OTC:MYCOF) Stock
Mydecine Innovations Gr Stock (OTC: MYCOF)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Monday, October 28, 2024
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
Juan Spínelli
Wednesday, July 31, 2024
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Javier Hasse
Thursday, February 15, 2024
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
Lara Goldstein
Monday, October 16, 2023
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
Lara Goldstein
Thursday, October 12, 2023
Psychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth Market
Nina Zdinjak
Monday, August 21, 2023
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
Lara Goldstein
Tuesday, August 15, 2023
Mydecine Releases Q2 2023: Developer Of Smoke Cessation Psilocybin Prodrugs & MDMA Analogs
Lara Goldstein
Tuesday, August 01, 2023
Jamaica Launches Organic Psilocybin Gummies & New Psychedelic Retreat: Rose Hill's New Offer
Lara Goldstein
Wednesday, May 31, 2023
Mydecine's Prospectus Supplement Closing Under Share Subscription And Management Update
Lara Goldstein
Tuesday, May 23, 2023
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Lara Goldstein
Wednesday, May 17, 2023
Mydecine's Q1 2023 Reports Shows Decline In Assets And R&D, Increase In Net Loss And Accumulated Deficit
Lara Goldstein
Monday, May 01, 2023
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
Lara Goldstein
Tuesday, April 25, 2023
New Set Of MDMA Analogs To Hit The Clinic: These Are The Latest Positive Findings
Lara Goldstein
Monday, April 03, 2023
Mydecine: 2022 Financials & Business Update By Next-Gen Psychedelics Producer, Smoke Cessation Trial And More
Lara Goldstein
Wednesday, January 04, 2023
These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
Lara Goldstein
Tuesday, December 20, 2022
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
Lara Goldstein
Tuesday, December 13, 2022
Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business
Lara Goldstein
Tuesday, November 22, 2022
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Lara Goldstein
Tuesday, November 15, 2022
Mydecine's Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months
Lara Goldstein
Monday, September 26, 2022
Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements
Lara Goldstein
Friday, September 23, 2022
Will Cannabis Entrepreneurs Switch To Psychedelics?
Andrew Ward
Tuesday, August 30, 2022
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
Lara Goldstein
Friday, August 19, 2022
Mydecine Innovations Group Announces Private ...
Benzinga Newsdesk
Tuesday, August 16, 2022
Mydecine Innovations Group Reports Q2 Financial Results And Management Updates
Lara Goldstein
Thursday, July 21, 2022
Understanding The Psilocybin Supply Chain: Every Production Method Explained
Natan Ponieman
Tuesday, July 19, 2022
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
Lara Goldstein
Friday, June 17, 2022
Government-Funded Smoking Cessation Trial Uses Mydecine's New Psilocybin-Derived MYCO-001, Recently FDA-Approved
Lara Goldstein
Thursday, April 14, 2022
Mydecine Announces 1-for-50 Reverse Stock Split
Fermin Orgambide
Wednesday, April 06, 2022
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
Natan Ponieman
Friday, April 01, 2022
Mydecine Reports Financial Results For 2021
Fermin Orgambide
Wednesday, February 09, 2022
Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
Benzinga Cannabis
Friday, December 17, 2021
Mind Medicine to Study Effect of Time on LSD Microdosing
InvestorBrandNetwork
-
Sponsored
Tuesday, November 16, 2021
Mydecine: Q3 Financials, Advances Research On Psychedelic Therapies For Mental Health & Addiction Disorders
Jelena Martinovic
Thursday, November 04, 2021
The Legacy Of Dr. Aaron Beck, Father Of Cognitive Therapy, Lives On In Psychedelic Medicine
Natan Ponieman
Wednesday, October 20, 2021
Historic: Federal Agency Awards Grant For Psychedelics Research, First Time In 50 years
Natan Ponieman
Monday, September 27, 2021
Mydecine On Verge Of Finalizing Spin-Out Of Cannabis Subsidiaries, Obtains Shareholder And Court Approval
Jelena Martinovic
Saturday, September 18, 2021
Mydecine Announces New Clinical Trial For Smoking Cessation
Microdose Psychedelic Insights
Monday, September 13, 2021
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Natan Ponieman
Thursday, August 26, 2021
PharmaDrug Strikes Deal With Johns Hopkins University For A Clinical Trial Into Psychedelic DMT
Natan Ponieman
Monday, August 23, 2021
Psyched: Beckley Psytech Raises $80M, Diamond Therapeutics To Study Psilocybin Microdosing, Mydecine and Johns Hopkins Partner Up
Natan Ponieman
Wednesday, August 18, 2021
Mydecine Innovations Inks Deal With Johns Hopkins University To Undertake Psychedelics Research Into Smoking Cessation
Natan Ponieman
Tuesday, August 03, 2021
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
Natan Ponieman
Friday, July 02, 2021
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Natan Ponieman
Wednesday, June 30, 2021
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Natan Ponieman
Monday, June 21, 2021
Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform
Natan Ponieman
Thursday, June 17, 2021
Mydecine Identifies 4 Psychedelic-Related Drugs to Tackle the Mental Health Crisis
Shashank Jacob
Wednesday, June 16, 2021
Mydecine Innovations Group Launches AI-Assisted Drug Discovery Program
Natan Ponieman
Friday, May 28, 2021
Psyched: Nasdaq Gets Its Third Psychedelics Company, Mynd Goes Public, Delic Buys New Research Facility
Natan Ponieman
Wednesday, May 19, 2021
Mydecine To Spin-Out Its U.S. Cannabis Assets By Mid July
Jelena Martinovic
Show More
